Saltar al contenido
Merck

Perfluorodecalin lavage of a longstanding lung atelectasis in a child with spinal muscle atrophy.

Pediatric pulmonology (2011-10-19)
Thore Henrichsen, Paal H H Lindenskov, Thomas H Shaffer, Ruth J V Loekke, Drude Fugelseth, Rolf Lindemann
RESUMEN

Persistent lung atelectasis is difficult to treat and perfluorochemical (PFC) liquid may be an option for bronchioalveolar lavage (BAL). A 4-year-old girl with spinal muscle atrophy was admitted in respiratory failure. On admission, the X-ray confirmed the persistence of total right-sided lung atelectasis, which had been present for 14 months. She was endotracheally intubated and ventilated from the day of admission. BAL with normal saline was performed twice without improvement. Following failed extubation and being dependent on continuous respiratory support, a trial of BAL using PFC liquid (Perfluorodecalin HP) was carried out. The PFC was delivered through the endotracheal tube on three consecutive days. A loading dose of 3 ml/kg was administered, followed by a varying dose in order to more effectively lavage the lungs. She tolerated the procedure well the first 2 days, although there were no clinical signs of improvement in the atelectasis. Intentionally, higher inflation pressures were applied after PFC instillation on day 3. Chest X-ray then showed hazy infiltrates on her left lung and she required more ventilatory support. However, lung infiltrates cleared over the next 3 days. A tracheotomy was done 6 days after the last PFC instillation. She had a slow recovery and was successfully decanulated. Clinical improvement of lung function was seen including less need of BiPAP and oxygen. A chest CT scan showed then functional lung tissue appearing in the previous total atelectatic right lung. Lavage with PFC can safely be performed with a therapeutic effect in a child with unilateral total lung atelectasis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Perfluorodecalin, 95%
Sigma-Aldrich
Octadecafluorodecahydronaphthalene, (cis+trans), ≥94% (GC)